Evidence map›Paper›PMID 39979051›Full record

ArticleBMJ open2025

Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol.

Daphnée Brazeau, Amelie A Deshaies, David Williamson, Francis Bernard, Caroline Arbour, Anne Marie Pinard, Dominique Rouleau, Louis De Beaumont

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06448923 (Effects of an Acute 1-month Cannabidiol Treatment on Pain and Inflammation After a Long Bone Fracture), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06448923 phase2recruitingnot on this map

Effects of an Acute 1-month Cannabidiol Treatment on Pain and Inflammation After a Long Bone Fracture: a Triple-blind Randomized, Placebo Controlled Clinical Trial

TypeinterventionalSponsorCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealRan2025 to 2027Enrolled225ConditionsFractureArmsCannabidiol, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daphnée BrazeauPsychology, University of Montreal, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0002-3836-4227
Amelie A DeshaiesCIUSSS du Nord-de-l'Ile-de-Montreal, Montreal, Quebec, Canada.
David WilliamsonCIUSSS du Nord-de-l'Ile-de-Montreal, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0003-3360-4831
Francis BernardHopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada.
Caroline ArbourCIUSSS du Nord-de-l'Ile-de-Montreal, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0002-9952-0588
Anne Marie PinardUniversité Laval, Montreal, Quebec, Canada.
Dominique RouleauHopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada.
Louis De BeaumontCIUSSS du Nord-de-l'Ile-de-Montreal, Montreal, Quebec, Canada louis.de.beaumont@umontreal.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute pain levels following orthopaedic injury (eg, fracture) are a predictor of the onset of chronic pain, which affects nearly 50% of fracture patients and impairs functional recovery. Among current pharmacological treatments for acute pain, non-steroidal anti-inflammatory drugs have been associated with delayed bone healing, while opioids inhibit effective bone remodelling, increase the risk of pseudarthrosis and carry a high risk of addiction. In light of this, the development of new pain treatments is essential. Cannabidiol (CBD), a non-addictive and non-psychotropic cannabis component stands out as a potential therapeutic agent, given its analgesic and anti-inflammatory properties as well as its potential benefits for bone healing. This randomised controlled trial aims to investigate the effect of acute CBD treatment, compared with placebo, on patients' self-reported pain, inflammation and well-being following a fracture injury. METHODS AND ANALYSIS: This is a triple-blind, randomised, placebo-controlled clinical trial. A total of 225 adults aged 18-70 years, who have suffered a long bone fracture and were treated at the Hôpital du Sacré-Coeur de Montréal, will be randomly assigned within 1 week to one of three treatment arms (25 mg or 50 mg of CBD or placebo) for 1 month. The primary outcome will be the difference in the pain score between groups at 1-month follow-up. Secondary outcomes will include measures of persistent pain, inflammation, opioid usage, quality of life, sleep quality, depression, anxiety, cognition and orthopaedic function. Data will be collected at baseline, 1-month and 3-month follow-ups. ETHICS AND DISSEMINATION: This study obtained a Health Canada licence for use of cannabis products. It has also been approved by Health Canada and the Research Ethics Board of the CIUSSS du Nord-de-l'Île-de-Montréal (Project ID 2025-2105). The findings will be published in a peer-reviewed journal and presented at local, national and international conferences. The trial's results will be made publicly available on the ClinicalTrials.gov database. TRIAL REGISTRATION NUMBER: NCT06448923.

Indexed as

Acute PainCannabidiolFractures, BoneInflammationAdolescentAdultAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedPain MeasurementQuality of LifeRandomized Controlled Trials as TopicYoung AdultCannabidiolClinical TrialFractures, BoneOrthopedicsPAIN MANAGEMENT

Identifiers

PMID39979051
PMCPMC11842986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.